General Information of the Compound
| Compound ID |
CP0073805
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
1-(3-hydroxyazetidin-1-yl)-2-(6-hydroxy-2-phenyl-2-adamantyl)ethanone
Show/Hide
|
||||||||||||||||||
| Synonyms |
11B-HSD-1 inhibitors (non-insulin dependent diabetes/obesity/metabolic syndrome), BMS
11B-HSD-1 inhibitors (non-insulin dependent diabetes/obesity/metabolic syndrome), Bristol-Myers Squibb
11beta-hydroxysteroid dehydrogenase-type 1 inhibitors (non-insulin dependent diabetes/obesity/metabolic syndrome), BMS
11beta-hydroxysteroid dehydrogenase-type 1 inhibitors (non-insulin dependent diabetes/obesity/metabolic syndrome), Bristol-Myers Squibb
BMS-816336
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C21H27NO3
|
||||||||||||||||||
| Molecular Weight |
341.451
|
||||||||||||||||||
| Canonical SMILES |
OC1CN(C1)C(=O)CC1(C2CC3CC1CC(C2)C3O)c1ccccc1
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C21H27NO3/c23-18-11-22(12-18)19(24)10-21(15-4-2-1-3-5-15)16-6-13-7-17(21)9-14(8-16)20(13)25/h1-5,13-14,16-18,20,23,25H,6-12H2
Show/Hide
|
||||||||||||||||||
| InChIKey |
OAAZMUGLOXGVNH-UHFFFAOYSA-N
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
Clinical Information about the Compound